Back

Cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease in the United States

1 September 2024 (17:48 - 18:00)
Organised by: Logo
Congress Presentation Part of: Disparities: insights into socioeconomic factors and cardiovascular health Health Economics ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Susan Hennessy

National Institute of Preventive Cardiology, Galway (Ireland)

4 More presentations in this session

Presentation thumbnail
Cost differences between oral anticoagulation therapies in atrial fibrillation patients
Mr O. Lehtonen (Kuopio, FI)
Abstract Slides Video
Presentation thumbnail
Disparities by region, age, and sex in cardiovascular disease burden attributable to high fasting plasma glucose in China, 2010-2018: a nationwide, population-based study.
Miss X. Cao (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Embedding a text message recall system to increase the uptake of cardiovascular screening in Australian general practice. Results of the Text to Detect randomised controlled trial
Miss N. Raffoul (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Independent associations of educational attainment and its joint associations with LE8 score for risk of cardiovascular disease incidence and mortality among Chinese people
Doctor Z. Chen (Changsha, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Disparities: insights into socioeconomic factors and cardiovascular health
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 17:48 CET
You may be interested in
thumbnail
Congress Presentation
Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial
thumbnail
Congress Presentation
Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis
thumbnail
Congress Presentation
Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources